Report overview
Coagulation Factor VIIa, recombinant is a coagulation factor indicated for: Treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann?s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets
This report contains market size and forecasts of Recombinant Activated Coagulation Factor VII in global, including the following market information:
Global Recombinant Activated Coagulation Factor VII Market Revenue, 2018-2023, 2023-2030, ($ millions)
Global Recombinant Activated Coagulation Factor VII Market Sales, 2018-2023, 2023-2030, (Units)
Global top five Recombinant Activated Coagulation Factor VII companies in 2022 (%)
The global Recombinant Activated Coagulation Factor VII market was valued at million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period 2023-2030.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million by 2030.
Vial Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Recombinant Activated Coagulation Factor VII include Novo Nordisk, LFB SA HEMA Biologics and AryoGen Pharmed, etc. In 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Recombinant Activated Coagulation Factor VII manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Recombinant Activated Coagulation Factor VII Market, by Type, 2018-2023, 2023-2030 ($ Millions) & (Units)
Global Recombinant Activated Coagulation Factor VII Market Segment Percentages, by Type, 2022 (%)
Vial
Prefilled Syringe
Global Recombinant Activated Coagulation Factor VII Market, by Application, 2018-2023, 2023-2030 ($ Millions) & (Units)
Global Recombinant Activated Coagulation Factor VII Market Segment Percentages, by Application, 2022 (%)
Hemophilia A
Hemophilia B
Other
Global Recombinant Activated Coagulation Factor VII Market, By Region and Country, 2018-2023, 2023-2030 ($ Millions) & (Units)
Global Recombinant Activated Coagulation Factor VII Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Recombinant Activated Coagulation Factor VII revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Recombinant Activated Coagulation Factor VII revenues share in global market, 2022 (%)
Key companies Recombinant Activated Coagulation Factor VII sales in global market, 2018-2023 (Estimated), (Units)
Key companies Recombinant Activated Coagulation Factor VII sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novo Nordisk
LFB SA HEMA Biologics
AryoGen Pharmed
